Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.60 |
| ▸ | NQO2 | P16083 | 14/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2667002 | 0.93 | MTNR1A (0.59) | MTNR1ANQO2MTNR1B | |
| SCHEMBL5095627 | 0.87 | ESR1 (0.69) | MTNR1ANQO2MTNR1B | |
| SCHEMBL2667112 | 0.85 | MTNR1A (0.48) | MTNR1ANQO2MTNR1B | |
| SCHEMBL2877992 | 0.83 | CYP26A1 (0.76) | — | |
| SCHEMBL2875252 | 0.79 | MTNR1A (0.43) | MTNR1ANQO2MTNR1B | |
| SCHEMBL21743513 | 0.79 | HDAC1 (0.55) | MTNR1ANQO2MTNR1B | |
| SCHEMBL2873439 | 0.78 | SLC6A9 (0.47) | — | |
| SCHEMBL11403440 | 0.77 | MTNR1A (0.68) | MTNR1ANQO2MTNR1B | |
| SCHEMBL12394485 | 0.76 | MTNR1A (0.70) | MTNR1ANQO2MTNR1B | |
| SCHEMBL13938781 | 0.76 | MTNR1A (0.66) | MTNR1ANQO2MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | GPR119, PNLIP, SLC5A2 | MTNR1A 424/4885NQO2 603/4885MTNR1B 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.